ROBERT A WOLFF to Liver Neoplasms
This is a "connection" page, showing publications ROBERT A WOLFF has written about Liver Neoplasms.
Connection Strength
1.275
-
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63.
Score: 0.136
-
Microwave coagulation for liver metastases. Cochrane Database Syst Rev. 2024 03 27; 3:CD010163.
Score: 0.074
-
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
Score: 0.067
-
Bintrafusp alfa, an anti-PD-L1:TGF-? trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun. 2022 09; 2(9):979-986.
Score: 0.066
-
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
Score: 0.063
-
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021 06; 73(6):2278-2292.
Score: 0.061
-
Electrocoagulation for liver metastases. Cochrane Database Syst Rev. 2021 01 28; 1:CD009497.
Score: 0.059
-
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
Score: 0.058
-
Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. Cochrane Database Syst Rev. 2020 03 12; 3:CD009498.
Score: 0.056
-
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
Score: 0.053
-
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
Score: 0.046
-
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
Score: 0.046
-
Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926.
Score: 0.044
-
Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget. 2015 Aug 28; 6(25):21193-207.
Score: 0.041
-
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29.
Score: 0.039
-
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
Score: 0.037
-
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014 May 30; 5(10):3012-22.
Score: 0.037
-
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst. 2014 May 09; 106(5).
Score: 0.037
-
Microwave coagulation for liver metastases. Cochrane Database Syst Rev. 2013 Oct 13; (10):CD010163.
Score: 0.036
-
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
Score: 0.035
-
Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst Rev. 2013 Apr 30; (4):CD009498.
Score: 0.035
-
Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst Rev. 2012 Sep 12; (9):CD009498.
Score: 0.033
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.025
-
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005 Oct; 23(5):489-93.
Score: 0.020
-
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004 Aug 01; 101(3):578-86.
Score: 0.019
-
Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004 Apr; 239(4):450-8.
Score: 0.018
-
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys. 2001 Jan 01; 49(1):107-16.
Score: 0.015
-
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
Score: 0.013
-
Rate of bilirubin regression after stenting in malignant biliary obstruction for the initiation of chemotherapy: how soon should we repeat endoscopic retrograde cholangiopancreatography? Cancer. 2008 Jun; 112(11):2417-23.
Score: 0.006